Skip to main content
Springer logoLink to Springer
. 2025 Oct 18;399(3):3227–3233. doi: 10.1007/s00210-025-04708-5

Tribute to Alberto J. Kaumann

Torsten Christ 1, Ursula Ravens 2,
PMCID: PMC12935834  PMID: 41108359

Abstract

This review summarises the major contributions of Alberto J. Kaumann who died in December 2024. The German-born pharmacologist devoted his scientific life to the cardiovascular adrenergic and serotinergic systems. He classified the subtypes of the cardiac β-adrenoceptors (β-AR) into β1- and β2-AR using the subtype-selective antagonist. In addition, he showed that the dual coupling of β2-AR to Gαs- and Gαi-proteins plays a minor role in the healthy heart. He also found that the positive inotropic effect of serotonin (5-HT) was not mediated by release of noradrenaline, but due to activation of a specific 5-HT receptor coupled to Gαs-proteins. His experiments with prostaglandin-E1 demonstrated an increase in cAMP and spontaneous beating frequency of the heart in the absence of a positive inotropic effect, suggesting a compartmentation of cAMP. This finding was later verified by experiments with subtype-selective phosphodiesterase inhibitors. Last not least, he explained the antiarrhythmic effect of sotalol by prolongation of the cardiac action potential duration, providing for the first time, what was years later to be defined as class III antiarrhythmic action. With Alberto Kaumann, we have lost a colleague and friend who had dedicated his life to science and music.

Keywords: Cardiovascular adrenergic and serotonergic systems, β-adrenoceptors, cAMP


Alberto Julio Kaumann, a lone wolf in Pharmacology, died on December 26, 2024, in Alicante (Spain) at the home of his son. With him, we lose a dedicated, headstrong colleague who was not easily impressed by any new trendy research directions but pursued his own ideas with great consequence and perseverance. He loved the beauty of experimental work and science. His first published paper “Heart rate acceleration by imipramine and by noradrenaline after imipramine; its blockade by dichloroisoproterenol (DCL)” (Kaumann et al. 1962) reads like a revelation of his life-long scientific passion.

Born into an old Jewish merchant family in Hamburg, he had to leave Germany as a small boy together with his mother and younger brother in order to find refuge in Buenos Aires. In the turmoil of post-war times, his mother disappeared and left him to care for his brother. Besides making a living by delivering letters and catching frogs, which he sold to restaurants, he was eager to learn whatever there was to know. He made it into Medical School in Buenos Aires and joined the Department of Pharmacology while still a student. It was here that he discovered his love for science and therefore went on to one of the best Pharmacological Departments in the USA, at Harvard Medical School. He returned to Argentina with the intention of pursuing a career in Pharmacology. However, the political turmoil forced him to leave his country. Luckily, he found refuge and a new scientific habitat upon invitation of the late Physiologist Raimund Kaufmann at the Institute of Clinical Physiology, University of Düsseldorf. During this period, Alberto frequently travelled to East Germany to work with Albert Wollenberger, the inventor of the famous Wollenberger-clamp for rapid freezing of myocardial tissue samples (Wollenberger et al. 1960). Eventually, the Nobel prize winner James Black persuaded Alberto to join Imperial Chemical Industries (ICI), where he stayed until retirement. Although he had his official scientific home in the Department of Physiology at Cambridge University, his retirement marks the beginning of scientific wandering around the world, spending various periods of time in the laboratories of scientific friends in Oslo, Brisbane, Dresden, and Murcia. As frailty because of old age increased, he was taken care of by his son in Alicante.

Scientific achievements

Right from his very first encounter with science, Alberto became fascinated by the cardiovascular adrenergic and serotoninergic systems to which he devoted his entire scientific oeuvre. Independent in his thinking and always sceptical about results from experiments he did not conduct himself, he has nevertheless published 206 scientific papers, of which 79 appeared in Naunyn–Schmiedeberg’s Archives of Pharmacology. In fact, he holds rank six among the 15 most cited authors in our journal (Fig. 1; Dats et al. 2023).

Fig. 1.

Fig. 1

Top 15 contributors to Naunyn–Schmiedeberg’s Archives of Pharmacology. Red box marks position 6 for A. J. Kaumann.

Adapted from Dats et al. (2023), with permission of the publisher

Noradrenaline, adrenaline, and adrenoceptors

The large family of G-protein-coupled receptors (GPCR) includes receptors activated by sympathomimetic amines (adrenoreceptors, AR) that have been classified into α- and β-subgroups based on differences in responses observed in various organs (for review, see Ahlquist 1980). Further division of the β-AR subgroup was suggested to explain the different orders of potencies of various chemically modified agonists with respect to cardiostimulatory and bronchodilatory effects (Lands and Brown 1964). The cardiostimulatory receptor was designated β1-AR. The receptor mediating all other adaptations to acute stress, such as vascular and bronchial smooth muscle relaxation, increase in skeletal muscle strength, and glycogenolysis, was called β2-AR. The discrimination was rather simple, since noradrenaline preferentially activates β1-AR and is devoid of action on non-cardiac tissues, whereas adrenaline is considered to affect non-cardiac tissue via β2-AR. The well-known cardiostimulant effect of adrenaline could be easily explained by adrenaline’s ability to activate both β1- and β2-AR.

The final distinction between β1- and β2-AR became evident with the availability of new β-subtype-selective antagonists (Barrett et al. 1968). These compounds differentially attenuated the positive chronotropic effects of noradrenaline and adrenaline in cat right atria: While the unselective β-AR antagonist propranolol blocked the positive chronotropic effects of both noradrenaline and adrenaline, the selective β1-AR antagonist practolol only affected the response to noradrenaline, and the β2-AR antagonists H 35/15 that to adrenaline (Carlsson et al. 1972). These findings strongly suggested the existence of both β1- and β2-AR in the myocardium, which was later confirmed by radioligand binding studies (Stiles et al. 1983; Brodde et al. 1983) and cloning the receptors from human heart tissue (Frielle et al. 1987; Kobilka et al. 1987).

The discovery of β2-AR in the human heart appeared to offer a novel strategy for the treatment of heart failure: selective β2-AR agonists were expected to dilate coronary vessels and at the same time enhance force development. The latter effect seemed particularly useful since β2-AR was neither desensitized nor down-regulated in human heart failure (Bristow et al. 1986). Of the many groups working on this topic, it was Alberto Kaumann who demonstrated that in the human heart, selective β2-AR stimulation was associated with the disastrous side effects of catecholamines: the induction of arrhythmias (Kaumann and Sanders 1993).

Reliable pharmacological characterization of β-AR subtypes was hampered by the limited selectivity of either activating or inhibiting ligands; some of the antagonists even showed the phenomenon of intrinsic activity. For his entire remaining career, Alberto tackled these difficulties by consistently using the natural catecholamines for selective β1- and β2-AR activation: noradrenaline in the presence of the most selective β2-AR antagonists available, ICI 118,551, and adrenaline in the presence of the β1-AR antagonist CGP20712A. By this approach, he was able to dissect precisely β2-AR-dependent actions even in animals initially believed to be regulated purely by β1-AR (Christ et al. 2009).

Alberto has always been sceptical about universal truths. Thus, he described in much detail the apparently paradoxical effects of adrenaline in mice with cardiac overexpression of the human β2-AR. These findings suggested that β2-AR can couple both to Gαs and Gαi proteins (Heubach et al. 2003, 2004). Alberto spent considerable energy to emphasize that such effects probably result from the artificial overexpression that is not representative of the healthy human heart (Molenaar et al. 2007), although dual coupling of β2-AR to Gαs and Gαi had been shown before in ventricular cardiomyocytes from patients with severe heart failure (del Monte et al. 1993).

These early observations of differential effects of the two natural catecholamines noradrenaline and adrenaline by Alberto and his colleagues paved the way for even more sophisticated distinctions. Today, many new facets of signal transduction via cardiac adrenoceptors have been elucidated. One example is the concept of “biased” signaling by specific compounds, i.e., the preferential activation of one downstream pathway over the other when a receptor is coupled to more than a single G protein or signaling cascade (Ma et al. 2025). Inhibitors of G-protein-coupled receptor kinases, which prevent desensitization of β-AR upon prolonged stimulation, modulate the inotropic responses (Brand et al. 2024). In addition, recent evidence suggests that even within the same (murine) heart, individual cardiomyocytes do not express a constant pattern of β- and α-AR, but at least four distinct cardiomyocyte phenotypes with various patterns have been found (Myagmar et al. 2017).

Serotonin

Many cardiovascular pharmacologists will associate the name of Alberto Kaumann with serotonin (e.g., Kaumann 1983, 1990; Kaumann et al. 1994). The positive inotropic effect of serotonin (5-HT) has been known since the 1960s (Trendelenburg 1960) and was interpreted as serotonin-induced release of noradrenaline from intracardiac nerve endings. Inspired by Halima Ouadid (Ouadid et al. 1992), Alberto discovered that the 5-HT-induced enhancement of contractile force could be prevented and/or reversed by 5-HT receptor antagonists even when myocardial noradrenaline stores were emptied (Sanders and Kaumann 1992). Later, he could show that in the human heart, 5-HT receptor expression is not restricted to the atrium (Fig.2) (Kaumann and Levy 2006).

Fig. 2.

Fig. 2

Positive inotropic effect of serotonin in human left atrial preparations. Above: force of contraction (frequency of electrical stimulation 0.5 Hz) with increasing concentrations (in µM) of serotonin under control conditions (upper trace) and in the presence of the 5-HT receptor antagonist ICS 205–930 (tropisetron, 3 µM). Below: concentration–response curves for the above experiments (mean ± S.E.M, n = 6). From Sanders and Kaumann (1992) (with permission of the publisher)

Action potential-prolonging effect of the β-adrenoceptor antagonist sotalol

Less well-known are Alberto’s contributions to understanding the antiarrhythmic action of sotalol. Well before Vaughan Williams (Vaughan Williams 1975) suggested that prolongation of the cardiac action potential is an antiarrhythmic principle (class III action), Alberto wondered why the β-adrenoceptor antagonist sotalol had a positive inotropic effect despite the simultaneous presence of the standard β-adrenoceptor antagonist propranolol. In fact, sotalol increased isometric contraction amplitude in feline papillary muscle and even induced a small, but persisting aftercontraction. He postulated that this behavior could be due to a prolongation of the electrical excitation. It took him quite some persuasive effort to convince his colleague Camille Olson that action potential recordings would provide an answer to this riddle. The seminal observation of an enormously prolonged action potential duration after exposure to an admittedly extremely high concentration of sotalol (see Fig. 3) was published in Alberto’s first Science paper (Kaumann and Olson 1968).

Fig. 3.

Fig. 3

Action potentials (upper traces) and force of contraction (lower traces) of a kitten papillary muscle (stimulation frequency 0.2 Hz, 32.0–32.5 °C). A pre-drug control, B in the presence of sotalol (6 × 10.4 M, 30 min). Please note the different time scales in (A) and (B). From Kaumann and Olson (1968) (with permission of the publisher)

Compartmentation of cAMP

To the best of our knowledge, Kaumann and Birnbaumer (Kaumann and Birnbaumer 1974) provided the first evidence for compartmentation of cAMP, without coining the term as such. Based on similarities of chemical structural elements between catecholamines and prostaglandin-E1 (PG-E1), they investigated whether the two compounds would share a common receptor. They observed that PG-E1 produced a positive chronotropic effect in spontaneously beating kitten atria, that was not antagonised by propranolol, yet failed to enhance force of contraction despite a pronounced increase of cAMP in membranes from atrial and ventricular myocardium (Fig. 4). Thus, they could exclude the involvement of β-adrenoceptors in the cAMP increase and, at the same time, propose that there was a site of cAMP production that was not relevant for the force of contraction. Incidentally, cAMP production in response to 5-HT4 receptor stimulation was diminished in remodeled atrial tissue from patients with persistent atrial fibrillation, and so were the positive inotropic and arrhythmogenic effects (Christ et al. 2014). The reduced cAMP production and positive inotropic effect were rescued when both cAMP degrading enzymes phosphodiesterase 3 and 4 were inhibited, but the low arrhythmic response remained unaffected by the enzyme inhibition (Berk et al. 2016). These results were also interpreted as compartmentation of cAMP production and have been published in Alberto’s very last paper (Dolce et al. 2021).

Fig. 4.

Fig. 4

Left: PGE1 effects on intact atria: chronotropic effects in spontaneously beating right atria (top) and inotropic effects (bottom). Data for PGE1 in the presence of 100 nM propranolol are marked by an arrow. Right: Effects of (−)-isoprenaline (circles) and PGE1 (triangles) in the absence (open symbols) or presence (closed symbols) of 100 nM propranolol on cAMP in membrane particles of atria from kittens. From Kaumann and Birnbaumer (1974) (with permission of the publisher)

Alberto Kaumann dissected the often puzzling and controversial effects of GPCR stimulation with the help of receptor subtype-selective antagonists and by careful observation of different functional parameters such as force of contraction, spontaneous beating frequency, and cAMP generation. Thus, he could differentiate the functional consequences of β2-AR coupling to Gαs and Gαi proteins and provide the first evidence for cAMP compartmentation in responses to various GPCR stimulations (Fig. 5).

Fig. 5.

Fig. 5

Schematic of two major contributions by Alberto Kaumann. The cardiac GPCR with the highest binding affinity for prostaglandin-E1 (PGE1), serotonin (5-HT), noradrenaline (NA), and adrenaline (Adr) are PGE1-R, 5-HT4-R, β1-AR, and β2-AR, respectively. All of them couple to Gαs proteins, stimulate cAMP production, and increase spontaneous beating rate, but produce differential positive inotropic effects (PIE), suggesting compartmentation of cAMP production. Please note that activation of Gαi by β2-AR stimulation is restricted to mice overexpressing β2-AR

Concluding remarks about a special personality

Alberto Kaumann led a modest daily life (Fig. 6), but had the highest demands on himself and others concerning science and music. He boundlessly admired Johann Sebastian Bach’s music for its precision and genial musicality, and was able to factor out Bach’s known antisemitism. He was a passionate piano player, practicing every day for an hour or two. Not only did he love to play for himself, but also for colleagues or—when in Dresden—even for residents of an old people’s home.

Fig. 6.

Fig. 6

Alberto Kaumann in the Department of Pharmacology at the University of Murcia, Murcia, Spain (by courtesy of Dr. Alejandro Galindo-Tovar)

In an interview, one of the authors (UR) described Alberto Kaumann’s impact on pharmacology as “a fine example of how simple experimental methods, like measuring force of contraction in isolated atrial muscle strips, are still useful for resolving pharmacological problems if the results are interpreted by a brilliant mind” (Circulation 2010: Spotlight in Cardiology). We, the authors, share with Alberto what he called the “libido” for science and music.

Acknowledgements

The authors gratefully acknowledge the informative details provided by Johann Goldmann, son of Alberto Kaumann.

Author contributions

T.C. and U.R. wrote the manuscript text. U.R. prepared the figures. All authors reviewed the manuscript. The authors declare that all data were generated in-house and that no paper mill was used.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Data availability

All source data for this work (or generated in this study) are available upon reasonable request.

Declarations

Ethics approval

Ethics, consent to participate, and consent to publish declarations: not applicable.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. Ahlquist RP (1980) Historical perspective. Classification of adrenoreceptors. J Auton Pharmacol 1(1):101–106. 10.1111/j.1474-8673.1980.tb00445.x [DOI] [PubMed] [Google Scholar]
  2. Barrett AM, Crowther AF, Dunlop D, Shanks RG, Smith LH (1968) Cardio-Selective Beta-Blockade Naunyn-Schmiedeberg’s Arch Pharmacol 259(2):152–153. 10.1007/bf00537746 [Google Scholar]
  3. Berk E, Christ T, Schwarz S, Ravens U, Knaut M, Kaumann AJ (2016) In permanent atrial fibrillation, PDE3 reduces force responses to 5-HT, but PDE3 and PDE4 do not cause the blunting of atrial arrhythmias. Br J Pharmacol 173(16):2478–2489. 10.1111/bph.13525 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brand T, Lukannek AK, Jahns V, Jahns R, Lorenz K (2024) From “contraindicated” to “first line” - current mechanistic insights beyond canonical β-receptor signaling. Curr Opin Pharmacol 76:102458. 10.1016/j.coph.2024.102458 [DOI] [PubMed] [Google Scholar]
  5. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S (1986) Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 59(3):297–309. 10.1161/01.res.59.3.297 [DOI] [PubMed] [Google Scholar]
  6. Brodde OE, Karad K, Zerkowski HR, Rohm N, Reidemeister JC (1983) Coexistence of beta 1- and beta 2-adrenoceptors in human right atrium. Direct identification by (+/-)-[125I]iodocyanopindolol binding. Circ Res 53(6):752–758. 10.1161/01.res.53.6.752 [DOI] [PubMed] [Google Scholar]
  7. Carlsson E, Ablad B, Brändström A, Carlsson B (1972) Differentiated blockade of the chronotropic effects of various adrenergic stimuli in the cat heart. Life Sci 11(20):953–958. 10.1016/0024-3205(72)90133-6 [Google Scholar]
  8. Christ T, Galindo-Tovar A, Thoms M, Ravens U, Kaumann AJ (2009) Inotropy and L-type Ca2+ current, activated by beta1- and beta2-adrenoceptors, are differently controlled by phosphodiesterases 3 and 4 in rat heart. Br J Pharmacol 156(1):62–83. 10.1111/j.1476-5381.2008.00015.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Christ T, Rozmaritsa N, Engel A, Berk E, Knaut M, Metzner K, Canteras M, Ravens U, Kaumann A (2014) Arrhythmias, elicited by catecholamines and serotonin, vanish in human chronic atrial fibrillation. Proc Natl Acad Sci U S A 111(30):11193–11198. 10.1073/pnas.1324132111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Circulation: European perspectives in cardiology. Spotlight: Ursula Ravens, MD, PhD, FESC, FAHA. Circulation September 14, 2010, f61-f63
  11. Dats LB, von Haugwitz F, Seifert R (2023) Bibliometric development of Naunyn-Schmiedeberg’s archives of pharmacology. Naunyn-Schmiedebergs Arch Pharmacol 396(1):43–61. 10.1007/s00210-022-02307-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. del Monte F, Kaumann AJ, Poole-Wilson PA, Wynne DG, Pepper J, Harding SE (1993) Coexistence of functioning beta 1- and beta 2-adrenoceptors in single myocytes from human ventricle. Circulation 88(3):854–863. 10.1161/01.cir.88.3.854 [DOI] [PubMed] [Google Scholar]
  13. Dolce B, Christ T, Grammatika Pavlidou N, Yildirim Y, Reichenspurner H, Eschenhagen T, Nikolaev VO, Kaumann AJ, Molina CE (2021) Impact of phosphodiesterases PDE3 and PDE4 on 5-hydroxytryptamine receptor4-mediated increase of cAMP in human atrial fibrillation. Naunyn-Schmiedebergs Arch Pharmacol 394(2):291–298. 10.1007/s00210-020-01968-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Frielle T, Collins S, Daniel KW, Caron MG, Lefkowitz RJ, Kobilka BK (1987) Cloning of the cDNA for the human beta 1-adrenergic receptor. Proc Natl Acad Sci U S A 84(22):7920–7924. 10.1073/pnas.84.22.7920 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Heubach JF, Blaschke M, Harding SE, Ravens U, Kaumann AJ (2003) Cardiostimulant and cardiodepressant effects through overexpressed human beta2-adrenoceptors in murine heart: regional differences and functional role of beta1-adrenoceptors. Naunyn-Schmiedebergs Arch Pharmacol 367(4):380–390. 10.1007/s00210-002-0681-4 [DOI] [PubMed] [Google Scholar]
  16. Heubach JF, Ravens U, Kaumann AJ (2004) Epinephrine activates both Gs and Gi pathways, but norepinephrine activates only the Gs pathway through human beta2-adrenoceptors overexpressed in mouse heart. Mol Pharmacol 65(5):1313–1322. 10.1124/mol.65.5.1313 [DOI] [PubMed] [Google Scholar]
  17. Kaumann AJ (1983) Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors. Naunyn-Schmiedebergs Arch Pharmacol 323(2):149–154. 10.1007/bf00634263 [DOI] [PubMed] [Google Scholar]
  18. Kaumann AJ (1990) Piglet sinoatrial 5-HT receptors resemble human atrial 5-HT4-like receptors. Naunyn-Schmiedebergs Arch Pharmacol 342(5):619–622. 10.1007/bf00169055 [DOI] [PubMed] [Google Scholar]
  19. Kaumann AJ, Birnbaumer L (1974) Prostaglandin E1 action on sinus pacemaker and adenylyl cyclase in kitten myocardium. Nature 251(5475):515–517. 10.1038/251515a0 [DOI] [PubMed] [Google Scholar]
  20. Kaumann AJ, Levy FO (2006) 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther 111(3):674–706. 10.1016/j.pharmthera.2005.12.004 [DOI] [PubMed] [Google Scholar]
  21. Kaumann AJ, Olson CB (1968) Temporal relation between long-lasting aftercontractions and action potentials in cat papillary muscles. Science 161(3838):293–295. 10.1126/science.161.3838.293 [DOI] [PubMed] [Google Scholar]
  22. Kaumann AJ, Sanders L (1993) Both beta 1- and beta 2-adrenoceptors mediate catecholamine-evoked arrhythmias in isolated human right atrium. Naunyn-Schmiedebergs Arch Pharmacol 348(5):536–540. 10.1007/bf00173215 [DOI] [PubMed] [Google Scholar]
  23. Kaumann AJ, Coussio JD, Izquierdo JA (1962) Heart rate acceleration by imipramine and by noradrenaline after imipramine; its blockade by dichloroisoproterenol (DCL). Med Exp Int J Exp Med 6:33–38. 10.1159/000135131 [DOI] [PubMed] [Google Scholar]
  24. Kaumann AJ, Gaster LM, King FD, Brown AM (1994) Blockade of human atrial 5-HT4 receptors by SB 207710, a selective and high affinity 5-HT4 receptor antagonist. Naunyn-Schmiedebergs Arch Pharmacol 349(5):546–548. 10.1007/bf00169146 [DOI] [PubMed] [Google Scholar]
  25. Kobilka BK, Dixon RA, Frielle T, Dohlman HG, Bolanowski MA, Sigal IS, Yang-Feng TL, Francke U, Caron MG, Lefkowitz RJ (1987) cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci U S A 84(1):46–50. 10.1073/pnas.84.1.46 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lands AM, Brown TG Jr (1964) A comparison of the cardiac stimulating and bronchodilator actions of selected sympathomimetic amines. Proc Soc Exp Biol Med 116:331–333. 10.3181/00379727-116-29239
  27. Ma Y, Patterson B, Zhu L (2025) Biased signaling in GPCRs: structural insights and implications for drug development. Pharmacol Ther 266:108786. 10.1016/j.pharmthera.2024.108786 [DOI] [PubMed] [Google Scholar]
  28. Molenaar P, Savarimuthu SM, Sarsero D, Chen L, Semmler AB, Carle A, Yang I, Bartel S, Vetter D, Beyerdörfer I, Krause EG, Kaumann AJ (2007) (-)-Adrenaline elicits positive inotropic, lusitropic, and biochemical effects through β2-adrenoceptors in human atrial myocardium from nonfailing and failing hearts, consistent with Gs coupling but not with Gi coupling. Naunyn-Schmiedebergs Arch Pharmacol 375(1):11–28. 10.1007/s00210-007-0138-x [DOI] [PubMed] [Google Scholar]
  29. Myagmar BE, Flynn JM, Cowley PM, Swigart PM, Montgomery MD, Thai K, Nair D, Gupta R, Deng DX, Hosoda C, Melov S, Baker AJ, Simpson PC (2017) Adrenergic receptors in individual ventricular myocytes: the beta-1 and alpha-1B are in all cells, the alpha-1A is in a subpopulation, and the beta-2 and beta-3 are mostly absent. Circ Res 120(7):1103–1115. 10.1161/circresaha.117.310520 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Ouadid H, Seguin J, Dumuis A, Bockaert J, Nargeot J (1992) Serotonin increases calcium current in human atrial myocytes via the newly described 5-hydroxytryptamine4 receptors. Mol Pharmacol 41(2):346–351 [PubMed] [Google Scholar]
  31. Sanders L, Kaumann AJ (1992) A 5-HT4-like receptor in human left atrium. Naunyn-Schmiedebergs Arch Pharmacol 345(4):382–386. 10.1007/bf00176614 [DOI] [PubMed] [Google Scholar]
  32. Stiles GL, Taylor S, Lefkowitz RJ (1983) Human cardiac beta-adrenergic receptors: subtype heterogeneity delineated by direct radioligand binding. Life Sci 33(5):467–473. 10.1016/0024-3205(83)90796-8 [DOI] [PubMed] [Google Scholar]
  33. Trendelenburg U (1960) The action of histamine and 5-hydroxytryptamine on isolated mammalian atria. J Pharmacol Exp Ther 130:450–460 [PubMed] [Google Scholar]
  34. Vaughan Williams EM (1975) Classification of antidysrhythmic drugs. Pharmacol Ther B 1(1):115–138. 10.1016/0306-039x(75)90019-7 [DOI] [PubMed] [Google Scholar]
  35. Wollenberger A, Ristau O, Schoffa G (1960) A simple technic for extremely rapid freezing of large pieces of tissue. Pflugers Arch Eur J Physiol 270:399–412 [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

All source data for this work (or generated in this study) are available upon reasonable request.


Articles from Naunyn-Schmiedeberg's Archives of Pharmacology are provided here courtesy of Springer

RESOURCES